Exploring the role of the immune response in preventing antibiotic resistance

Journal of Theoretical Biology

Volumn 256, Issue 4, 2009, Pages 655-662

  Handel, Andreas ^a   Margolis, Elisa ^a   Levin, Bruce R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Antibiotic treatment; Bacterial infection dynamics; Drug resistance; Immune response; Mutant selection window

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL DISEASE; DEFENSE MECHANISM; DRUG RESISTANCE; IMMUNE RESPONSE; MUTATION; NUMERICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNITY, CELLULAR; MODELS, IMMUNOLOGICAL; MUTATION; PATIENT COMPLIANCE; SELECTION (GENETICS);

BACTERIA (MICROORGANISMS);

EID: 58649103313     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2008.10.025     Document Type: Article

References (62)

1. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., and Drusano G.L. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44 1 (2007) 79-86. http://dx.doi.org/10.1086/510079 URL 〈http://dx.doi.org/10.1086/510079〉
2. Andes D., and Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19 4 (2002) 261-268
3. Antia R., Bergstrom C.T., Pilyugin S.S., Kaech S.M., and Ahmed R. Models of CD8+ responses: 1. What is the antigen-independent proliferation program. J. Theor. Biol. 221 4 (2003) 585-598
4. Austin D.J., White N.J., and Anderson R.M. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194 3 (1998) 313-339. http://dx.doi.org/10.1006/jtbi.1997.0438 URL 〈http://dx.doi.org/10.1006/jtbi.1997.0438〉
5. Bajenoff M., Wurtz O., and Guerder S. Repeated antigen exposure is necessary for the differentiation, but not the initial proliferation, of naive CD4(+) T cells. J. Immunol. 168 4 (2002) 1723-1729
6. Bull J.J., Levin B.R., DeRouin T., Walker N., and Bloch C.A. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2 (2002) 35
7. Campion J.J., McNamara P.J., and Evans M.E. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49 1 (2005) 209-219. http://dx.doi.org/10.1128/AAC.49.1.209-219.2005 URL 〈http://dx.doi.org/10.1128/AAC.49.1.209-219.2005〉
8. Chung P., McNamara P.J., Campion J.J., and Evans M.E. Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 50 9 (2006) 2957-2965. http://dx.doi.org/10.1128/AAC.00736-05 URL 〈http://dx.doi.org/10.1128/AAC.00736-05〉
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 1 (1998) 1-10 quiz 11-2
10. Curlin M.E., Iyer S., and Mittler J.E. Optimal timing and duration of induction therapy for hiv-1 infection. PLoS Comput. Biol. 3 7 (2007) e133. http://dx.doi.org/10.1371/journal.pcbi.0030133 URL 〈http://dx.doi.org/10.1371/journal.pcbi.0030133〉
11. Dalhoff A. Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model. Infection 33 Suppl. 2 (2005) 44-49. http://dx.doi.org/10.1007/s15010-005-8207-x URL 〈http://dx.doi.org/10.1007/s15010-005-8207-x〉
12. Dalhoff A., and Schmitz F.-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22 4 (2003) 203-221. http://dx.doi.org/10.1007/s10096-003-0907-5 URL 〈http://dx.doi.org/10.1007/s10096-003-0907-5〉
13. Dalhoff A., and Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3 6 (2003) 359-371
14. De Boer R., Oprea M., Antia R., Murali-Krishna K., Ahmed R., and Perelson A. Recruitment times, proliferation, and apoptosis rates during the CD8(+) T-cell response to lymphocytic choriomeningitis virus. J. Virol. 75 22 (2001) 10663-10669. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?cmd=prlinks &dbfrom=pubmed&retmode=ref&id=11602708 URL 〈http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?cmd=prlink s&dbfrom=pubmed&retmode=ref&id=11602708〉
15. De Boer R.J., Homann D., and Perelson A.S. Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171 8 (2003) 3928-3935
16. DeRyke C.A., Lee S.Y., Kuti J.L., and Nicolau D.P. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 66 1 (2006) 1-14
17. Dhar N., and McKinney J.D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. Opin. Microbiol. 10 1 (2007) 30-38. http://dx.doi.org/10.1016/j.mib.2006.12.007 URL 〈http://dx.doi.org/10.1016/j.mib.2006.12.007〉
18. Drlica K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52 1 (2003) 11-17. http://dx.doi.org/10.1093/jac/dkg269 URL 〈http://dx.doi.org/10.1093/jac/dkg269〉
19. Drlica K., and Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44 5 (2007) 681-688. http://dx.doi.org/10.1086/511642 URL 〈http://dx.doi.org/10.1086/511642〉
20. Drlica K., and Zhao X.L. Is 'dosing-to-cure' appropriate in the face of antimicrobial resistance?. Rev. Med. Microbiol. 15 2 (2004) 73-80
21. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2 4 (2004) 289-300. http://dx.doi.org/10.1038/nrmicro862 URL 〈http://dx.doi.org/10.1038/nrmicro862〉
22. Fritz R.S., Hayden F.G., Calfee D.P., Cass L.M., Peng A.W., Alvord W.G., Strober W., and Straus S.E. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis. 180 3 (1999) 586-593
23. Gillespie S.H. Evolution of drug resistance in mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46 2 (2002) 267-274
24. Gomez J.E., and McKinney J.D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84 1-2 (2004) 29-44
25. Green D.R., Droin N., and Pinkoski M. Activation-induced cell death in t cells. Immunol. Rev. 193 (2003) 70-81
26. Happel K.I., Bagby G.J., and Nelson S. Host defense and bacterial pneumonia. Semin. Respir. Crit. Care Med. 25 1 (2004) 43-52. http://dx.doi.org/10.1055/s-2004-822304 URL 〈http://dx.doi.org/10.1055/s-2004-822304〉
27. Hayden F.G., Fritz R., Lobo M.C., Alvord W., Strober W., and Straus S.E. Local and systemic cytokine responses during experimental human influenza A virus infection, Relation to symptom formation and host defense. J. Clin. Invest. 101 3 (1998) 643-649
28. Hogan D., and Kolter R. Why are bacteria refractory to antimicrobials?. Curr. Opin. Microbiol. 5 5 (2002) 472-477
29. Imran M., and Smith H.L. The dynamics of bacterial infection, innate immune response, and antibiotic treatment. Discrete Continuous Dynamical Syst. Ser. B 8 1 (2007) 127-143
30. Jumbe N., Louie A., Leary R., Liu W., Deziel M.R., Tam V.H., Bachhawat R., Freeman C., Kahn J.B., Bush K., Dudley M.N., Miller M.H., and Drusano G.L. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112 2 (2003) 275-285. http://dx.doi.org/10.1172/JCI200316814 URL 〈http://dx.doi.org/10.1172/JCI200316814〉
31. Kaech S., and Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2 (2001) 415-422
32. Kamath A., Woodworth J.S.M., and Behar S.M. Antigen-specific cd8+ t cells and the development of central memory during mycobacterium tuberculosis infection. J. Immunol. 177 9 (2006) 6361-6369
33. Kamath A.B., Woodworth J., Xiong X., Taylor C., Weng Y., and Behar S.M. Cytolytic cd8+ t cells recognizing cfp10 are recruited to the lung after mycobacterium tuberculosis infection. J. Exp. Med. 200 11 (2004) 1479-1489. http://dx.doi.org/10.1084/jem.20041690 URL 〈http://dx.doi.org/10.1084/jem.20041690〉
34. Labro M.T. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?. Clin. Microbiol. Rev. 13 4 (2000) 615-650
35. Lee W.T., Pasos G., Cecchini L., and Mittler J.N. Continued antigen stimulation is not required during cd4(+) t cell clonal expansion. J. Immunol. 168 4 (2002) 1682-1689
36. Leijh P.C., van den Barselaar M.T., van Zwet T.L., Dubbeldeman-Rempt I., and van Furth R. Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes. Immunology 37 2 (1979) 453-465
37. Levin B.R., and Rozen D.E. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4 7 (2006) 556-562. http://dx.doi.org/10.1038/nrmicro1445 URL 〈http://dx.doi.org/10.1038/nrmicro1445〉
38. Lewis K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5 1 (2007) 48-56. http://dx.doi.org/10.1038/nrmicro1557 URL 〈http://dx.doi.org/10.1038/nrmicro1557〉
39. Li Y., Karlin A., Loike J.D., and Silverstein S.C. A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc. Natl. Acad Sci. USA 99 12 (2002) 8289-8294. http://dx.doi.org/10.1073/pnas.122244799 URL 〈http://dx.doi.org/10.1073/pnas.122244799〉
40. Li Y., Karlin A., Loike J.D., and Silverstein S.C. Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J. Exp. Med. 200 5 (2004) 613-622. http://dx.doi.org/10.1084/jem.20040725 URL 〈http://dx.doi.org/10.1084/jem.20040725〉
41. Lipsitch M., and Levin B.R. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41 2 (1997) 363-373
42. Lipsitch M., and Levin B.R. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis. 2 3 (1998) 187-199
43. Mager D.E., Wyska E., and Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31 5 (2003) 510-518
44. McLoughlin R.M., Solinga R.M., Rich J., Zaleski K.J., Cocchiaro J.L., Risley A., Tzianabos A.O., and Lee J.C. Cd4+ t cells and cxc chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc. Natl. Acad. Sci. USA 103 27 (2006) 10408-10413. http://dx.doi.org/10.1073/pnas.0508961103 URL 〈http://dx.doi.org/10.1073/pnas.0508961103〉
45. Mempel T.R., Henrickson S.E., and Andrian U.H.V. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427 6970 (2004) 154-159. http://dx.doi.org/10.1038/nature02238 URL 〈http://dx.doi.org/10.1038/nature02238〉
46. Mercado R., Vijh S., Allen S.E., Kerksiek K., Pilip I.M., and Pamer E.G. Early programming of T cell populations responding to bacterial infection. J. Immunol. 165 12 (2000) 6833-6839
47. Mouton J.W., van Ogtrop M.L., Andes D., and Craig W.A. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob. Agents Chemother. 43 10 (1999) 2473-2478
48. Mueller M., de la Pena A., and Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48 2 (2004) 369-377
49. Negri M.C., Lipsitch M., Blazquez J., Levin B.R., and Baquero F. Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob. Agents Chemother. 44 9 (2000) 2485-2491
50. Pamer E.G. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4 10 (2004) 812-823. http://dx.doi.org/10.1038/nri1461 URL 〈http://dx.doi.org/10.1038/nri1461〉
51. Pamer E.G. Immune responses to commensal and environmental microbes. Nat. Immunol. 8 11 (2007) 1173-1178. http://dx.doi.org/10.1038/ni1526 URL 〈http://dx.doi.org/10.1038/ni1526〉
52. Pankey G.A., and Sabath L.D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38 6 (2004) 864-870. http://dx.doi.org/10.1086/381972 URL 〈http://dx.doi.org/10.1086/381972〉
53. Pilyugin S., and Antia R. Modeling immune responses with handling time. Bull. Math. Biol. 62 5 (2000) 869-890. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?cmd=prlinks &dbfrom=pubmed&retmode=ref&id=11016088 URL 〈http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?cmd=prlink s&dbfrom=pubmed&retmode=ref&id=11016088〉
54. Regoes R.R., Wiuff C., Zappala R.M., Garner K.N., Baquero F., and Levin B.R. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48 10 (2004) 3670-3676. http://dx.doi.org/10.1128/AAC.48.10.3670-3676.2004 URL 〈http://dx.doi.org/10.1128/AAC.48.10.3670-3676.2004〉
55. Regoes R.R., Barber D.L., Ahmed R., and Antia R. Estimation of the rate of killing by cytotoxic T lymphocytes in vivo. Proc. Natl. Acad. Sci. USA 104 5 (2007) 1599-1603. http://dx.doi.org/10.1073/pnas.0508830104 URL 〈http://dx.doi.org/10.1073/pnas.0508830104〉
56. Sacchettini J.C., Rubin E.J., and Freundlich J.S. Drugs versus bugs: in pursuit of the persistent predator mycobacterium tuberculosis. Nat. Rev. Microbiol. 6 1 (2008) 41-52. http://dx.doi.org/10.1038/nrmicro1816 URL 〈http://dx.doi.org/10.1038/nrmicro1816〉
57. Schentag J.J., Gilliland K.K., and Paladino J.A. What have we learned from pharmacokinetic and pharmacodynamic theories?. Clin. Infect. Dis. 32 Suppl. 1 (2001) S39-S46
58. Tsai W.C., and Standiford T.J. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr. Pharm. Des. 10 25 (2004) 3081-3093
59. van Stipdonk M.J.B., Lemmens E.E., and Schoenberger S. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 2 (2001) 415-422
60. Yates A., Graw F., Barber D.L., Ahmed R., Regoes R.R., and Antia R. Revisiting estimates of CTL killing rates in vivo. PLoS ONE 2 12 (2007) e1301. http://dx.doi.org/10.1371/journal.pone.0001301 URL 〈http://dx.doi.org/10.1371/journal.pone.0001301〉
61. Zhao X., and Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33 Suppl. 3 (2001) S147-S156
62. Zhao, X., Drlica, K., 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. URL 〈http://dx.doi.org/10.1093/jac/dkn229〉.